Tag: fruquintinib

November 29, 2018

Chi-Med Enters into Multiple Collaborations to Evaluate Combinations of Surufatinib and Fruquintinib with PD-1 Checkpoint Inhibitors

Hutchison China MediTech (AIM/Nasdaq: HCM) entered into four collaboration agreements to evaluate the safety, tolerability and efficacy of Chi-Med’s surufatinib...
November 16, 2018

Chi-Med Announces Phase III FALUCA Trial Results for Fruquintinib in Third-Line, Advanced Non-Small Cell Lung Cancer in China

Hutchison China MediTech (AIM/Nasdaq: HCM) today announces the outcome of FALUCA, its Phase III trial of fruquintinib in advanced non-small cell lung cancer patients...
September 5, 2018

Chi-Med Announces the Approval of Fruquintinib Capsules for Previously Treated Colorectal Cancer in China

Hutchison China MediTech (AIM/Nasdaq: HCM) today announces that fruquintinib capsules have been granted approval for drug registration by the National...